• Home
  • NEW DAY MEDICINE
  • 4 (78) 2025
  • 52 - 4 (78) 2025 - Voxidova D.A., Usmanova D.Dj. - ATRIAL FIBRILLATION AND STROKE PREVENTION: A COMPARATIVE ASSESSMENT OF APIXABAN AND ASPIRIN

52 - 4 (78) 2025 - Voxidova D.A., Usmanova D.Dj. - ATRIAL FIBRILLATION AND STROKE PREVENTION: A COMPARATIVE ASSESSMENT OF APIXABAN AND ASPIRIN

ATRIAL FIBRILLATION AND STROKE PREVENTION: A COMPARATIVE ASSESSMENT OF APIXABAN AND ASPIRIN

Voxidova D.A. - Tashkent Pediatric Medical Institute

Usmanova D.Dj. - Tashkent Pediatric Medical Institute

Khodjimetov D.N. - Republican Specialized Scientific Practical Medical Center of Neurosurgery (RSSPMCN)

Voxidov A.M. - Samarkand State Medical University Uzbekistan

Resume

Actuality. Atrial fibrillation significantly increases the risk of stroke, while vitamin K antagonists cannot always be used due to contraindications. Apixaban is a potential alternative, but data on its comparative effectiveness with aspirin in such patients remain insufficient. This study aims to assess the efficacy and safety of apixaban in preventing stroke and systemic embolism in this patient group. Objective: To evaluate the efficacy and safety of apixaban compared to aspirin in patients with atrial fibrillation who are contraindicated for vitamin K antagonists. Materials and Methods: A total of 103 patients were included in the study and randomized into two groups: apixaban (n=52) and aspirin (n=51). The incidence of stroke, systemic embolism, mortality, and bleeding risk were analyzed. Statistical analysis was performed using the chi-square test and relative risk (OR) estimation with a 95% confidence interval (CI). Results: Stroke or systemic embolism occurred significantly less frequently in the apixaban group (1.9% vs. 8%, p<0.001). The incidence of ischemic stroke was also lower (3.8% vs. 10%, p<0.001). The rate of major bleeding events remained low and did not differ between the groups (1.9% vs. 2%, p=0.88). Hospitalization due to cardiovascular causes was lower in the apixaban group (13.5% vs. 22%, p<0.001). Conclusion: Apixaban is a more effective option for preventing stroke and systemic embolism in patients with atrial fibrillation who are contraindicated for vitamin K antagonists, while not increasing the risk of major bleeding.

Keywords: atrial fibrillation, apixaban, aspirin, stroke, systemic embolism.

First page

312

Last page

318

For citation:Voxidova D.A., Usmanova D.Dj., Khodjimetov D.N., Voxidov A.M. - ATRIAL FIBRILLATION AND STROKE PREVENTION: A COMPARATIVE ASSESSMENT OF APIXABAN AND ASPIRIN//New Day in Medicine 4(78)2025 312-318 https://newdayworldmedicine.com/en/new_day_medicine/4-78-2025

List of References

  1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-2375.
  2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988.
  3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
  4. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
  5. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.
  6. Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with aspirin for the prevention of recurrent stroke and systemic embolism in patients with nonvalvular atrial fibrillation and a contraindication to vitamin K antagonists (NAVIGATE ESUS): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2018;17(12):1057-1067.
  7. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
  8. Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2012;125(16):2168-2176.
  9. Vokhidova D. A., Usmanova D. D. , Khodjimetov D.N., Vokhidov A.M. Molecular Molecular Markers in Ischemic Stroke : Genetic Polymorphisms and Risk Assessment. American Journal of Medicine and Medical Sciences 2024;14(9):2307-2310. DOI: 10.5923/j.ajmms.20241409.39.
  10. Вохидова Д.Н. Усманова, Д.Д., Ходжиметов Д.Н., Роль HIF-1α в развитие патогенеза ишемического повреждения головного мозга. “Проблемы биологии и медицины” 2020;1(116):214-218.
  11. Вохидова Д.А., Усманова Д.Д, Ходжиметов Д. Н, Вохидов А.М. Бахриддинова М. Оценка состояния магистральных артерий головы по данным ультразвукового дуплексного сканирования у пациентов с ишемическим инсультом. Неврология 2024;(99):5-7.

    file

    download